China’s AI drug discovery stocks surge on Novo Nordisk deal and 15th Five-Year Plan
On September 18-21, Chinese AI drug discovery and CRO concept stocks surged, led by Novogene’s 20% daily limit and Heyi Pharmaceutical’s 30% limit. The rally followed China’s 15th Five-Year Plan for pharmaceutical industry development, which emphasizes AI, quantum computing, and supercomputing in drug R&D. International catalysts included Novo Nordisk’s partnership with Anthropic and Anthropic’s acquisition of Coefficient Bio. Analysts see AI drug discovery entering a value-validation phase.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary awaiting refresh
Summary awaiting refresh
Cross-source coverage
Reporting timeline
AI Drug Discovery Stocks Surge on Anthropic Lab News and China's Five-Year Plan Support
On September 21, AI drug discovery (AIDD) stocks rallied in Chinese markets, with Nuohé Zhiyuan hitting its daily price limit within three minutes of opening. The surge followed dual catalysts: reports that AI firm Anthropic is building a wet laboratory in San Francisco to integrate computational and experimental biology, and China's release of the 15th Five-Year Plan for the pharmaceutical industry, which explicitly supports AI-powered drug development. Anthropic recently partnered with Novo Nordisk and acquired AI drug startup Coefficient Bio for $400 million. Domestically, ByteDance's spin-off AI drug company Xinsheng Tantu completed its first financing round at a $1.5 billion valuation. Brokerages including Dongwu Securities, Zhongtai Securities, Shanghai Securities, and Zheshang Securities issued positive outlooks, stating AI drug discovery is entering a value-validation phase with dry-wet lab integration as the core logic. Eight A-share concept stocks are forecast to double their net profits this year, according to consensus estimates from at least three brokerages. The article lists specific companies and their performance metrics, including Baiao Saitu, Baipu Saisi, and Diao'an Diagnostics.
Read sourceAI Drug Discovery Stocks Surge on Anthropic Lab Plans and China's 15th Five-Year Plan Support
On September 21, AI drug discovery (AIDD) concept stocks surged in China's A-share market, led by Novogene's 20% daily limit within three minutes of opening. The rally was driven by dual catalysts: overseas, AI firm Anthropic is reportedly building a wet laboratory in San Francisco to create a dry-wet experiment loop for AI-driven drug discovery, following its partnership with Novo Nordisk and acquisition of Coefficient Bio. Domestically, China's Ministry of Industry and Information Technology and nine other departments jointly issued the '15th Five-Year Plan' for pharmaceutical industry development, explicitly supporting AI-powered drug development as one of 25 key tasks. Brokerages including Dongwu Securities, Zhongtai Securities, Shanghai Securities, and Zheshang Securities published bullish notes, arguing that AI drug discovery is entering a value-validation phase with dry-wet closed loops becoming core. According to Oriental Fortune, 80 A-share stocks are involved in the AI drug discovery concept, with a combined market cap of about 1.25 trillion yuan. Analysts forecast that eight concept stocks, including Dian Diagnostics, Changchun High-Tech, and Zelgen Biopharma, could see net profit more than double this year, based on consensus estimates from at least three institutions.
AI Drug Discovery Stocks Surge in China on Novo Nordisk Deal and Government Plan
Shares of AI-powered drug discovery companies in China's A-share market rallied sharply on [date of article]. Novogene led the gains with a 20% daily limit rise, while Huiyu Pharmaceutical-W surged over 10%, and several other firms including Hongbo Medical, Yingsheng Life, and Pharmaron posted gains of 5-8%. The rally was attributed to two key catalysts. First, Danish pharmaceutical giant Novo Nordisk announced a partnership with AI company Anthropic to use its AI models, including Claude Science, for drug discovery and development. Second, China's Ministry of Industry and Information Technology, along with nine other government departments, jointly released the '15th Five-Year Plan for the Pharmaceutical Industry Development,' which explicitly calls for 'deepening AI empowerment and upgrading' and 'accelerating the AI-driven paradigm shift in pharmaceutical R&D and production management.' The plan also supports the application of frontier technologies such as AI and supercomputing in target discovery and molecular design.
Read sourceShow 3 older updatesHide older updates
AI Drug Discovery and CRO Concepts Rally; Novogene Hits 20% Daily Limit Up
On September 21, AI drug discovery and CRO (Contract Research Organization) concepts continued their strong performance in the Chinese stock market, with Novogene hitting its 20% daily limit up. Other companies including Hongbo Pharmaceutical, Chengdu Lead Sci-Tech, Boji Pharmaceutical, Berry Genomics, and Seli Medical also followed with gains. The rally was driven by a policy announcement on September 18, when China's Ministry of Industry and Information Technology (MIIT) and nine other departments jointly issued the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan proposes accelerating the empowerment of drug research and development through new technologies such as artificial intelligence, quantum computing, supercomputing, and computational medicine. It also explores new models for pharmaceutical and medical device production, including ultra-limited manufacturing, space-based drug production, and biomanufacturing. The report is attributed to CLS, a Chinese financial news outlet.
Read sourceAI Drug Discovery Stocks Surge on Novo Nordisk-Anthropic Deal and China Policy Support
On September 21, Chinese AI drug discovery (AI制药) stocks rallied sharply, driven by international and domestic catalysts. Internationally, Danish pharmaceutical giant Novo Nordisk announced a deep partnership with AI firm Anthropic to use its Claude Science platform for drug discovery, following Anthropic's $400 million acquisition of AI drug startup Coefficient Bio in April. Domestically, ByteDance's spun-off AI drug firm Xinshengtantu completed its first financing round at a $1.5 billion post-investment valuation. Chinese AI drug firms Insilico Medicine and XtalPi reported strong revenue growth. Policy support came from China's Ministry of Industry and Information Technology and nine other departments issuing the '15th Five-Year Plan' for pharmaceutical industry development, which emphasizes deepening AI applications. Analysts at China Securities and Shanghai Securities view AI drug discovery as entering a value validation phase, with potential for a 'Claude moment' in the pharmaceutical industry. The article identifies eight concept stocks expected to see net profit more than double this year, including Dian Diagnostics, Changchun High-Tech, and Zelgen Biopharmaceuticals.
Read sourceCRO Concept Stocks Surge on China's 15th Five-Year Plan for Pharmaceutical Industry
On September 18, China's CRO (Contract Research Organization) concept sector saw a sharp rally, with Heyi Pharmaceutical hitting a 30cm daily limit-up. Other stocks including Jinan Protein, Chengdu Xian Dao, and Hongbo Pharmaceutical rose over 10%. The surge followed the release of the '15th Five-Year Plan for the Pharmaceutical Industry Development' by ten government departments including the Ministry of Industry and Information Technology. The plan calls for accelerating the application of new technologies such as artificial intelligence, quantum computing, supercomputing, and computational medicine in drug research and development. It also explores new production models for pharmaceuticals and medical devices, including ultra-limit manufacturing, space pharmaceuticals, and biomanufacturing. The policy aims to boost innovation and modernization in China's pharmaceutical sector.
Read source